Citigroup Raises Integer (NYSE:ITGR) Price Target to $130.00

Integer (NYSE:ITGR) had its price target increased by Citigroup from $124.00 to $130.00 in a research report report published on Tuesday, Benzinga reports. Citigroup currently has a neutral rating on the medical equipment provider’s stock.

Other equities analysts have also issued reports about the stock. Benchmark reaffirmed a buy rating and set a $130.00 target price on shares of Integer in a report on Friday, August 2nd. Truist Financial lifted their target price on shares of Integer from $137.00 to $145.00 and gave the company a buy rating in a report on Tuesday. Oppenheimer began coverage on shares of Integer in a report on Tuesday, July 16th. They issued an outperform rating and a $135.00 price target for the company. Finally, Bank of America boosted their price target on shares of Integer from $135.00 to $145.00 and gave the stock a buy rating in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $137.29.

Integer Stock Down 1.1 %

Shares of ITGR opened at $125.81 on Tuesday. Integer has a 52 week low of $69.40 and a 52 week high of $131.87. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $4.22 billion, a price-to-earnings ratio of 43.53, a PEG ratio of 1.87 and a beta of 1.09. The stock’s 50-day moving average price is $123.63 and its 200-day moving average price is $119.41.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.06. The firm had revenue of $436.20 million for the quarter, compared to the consensus estimate of $437.00 million. Integer had a return on equity of 11.48% and a net margin of 6.31%. The company’s revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.14 earnings per share. On average, sell-side analysts predict that Integer will post 5.31 EPS for the current year.

Insider Transactions at Integer

In other news, Director Jean M. Hobby sold 11,960 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the completion of the sale, the director now owns 2,280 shares of the company’s stock, valued at $272,824.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Integer

A number of large investors have recently modified their holdings of the business. Quest Partners LLC boosted its position in shares of Integer by 3,688.9% during the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 332 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Integer by 60.9% during the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 142 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Integer during the 1st quarter valued at about $106,000. Innealta Capital LLC acquired a new position in shares of Integer during the 2nd quarter valued at about $110,000. Finally, Hancock Whitney Corp acquired a new position in shares of Integer during the 1st quarter valued at about $203,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.